Clinical Trial Detail

NCT ID NCT00092222
Title Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Kaposi's sarcoma

Therapies

Sirolimus

Alpha 2 Interferon

Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate

Rituximab

Bortezomib

Pegylated liposomal-doxorubicin

Age Groups: adult child

No variant requirements are available.